Interestingly, despite analogous structure and binding affinity to CD133, PP10, and PP24 affect downstream signaling pathways differently, leading to distinct anti-tumor mechanisms, as evaluated through multi-platform validation. This evidence concerns the gene PROM1 and neoplasm.